<DOC>
	<DOCNO>NCT00131352</DOCNO>
	<brief_summary>This clinical study evaluate safety efficacy hylan G-F 20 ( Synvisc ) patient symptomatic knee osteoarthritis ( OA ) . Patients give 6 mL hylan G-F 20 ( Synvisc ) ( phosphate buffer saline control ) , possible repeat treatment Synvisc week 26 visit .</brief_summary>
	<brief_title>A Study Safety Efficacy Hylan G-F 20 ( Synvisc ) Patients With Symptomatic Osteoarthritis Knee</brief_title>
	<detailed_description>The trial include initial 26 week treatment 6 mL hylan G-F 20 ( Synvisc ) ( phosphate buffer saline control ) follow 4 week repeat treatment Synvisc .</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Musculoskeletal Diseases</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Patient document diagnosis primary osteoarthritis ( OA ) target knee make least 3 month prior Screening , Has radiographic evidence OA tibiofemoral compartment target , knee least 1 definite osteophyte measureable joint space , diagnosed standard Xrays take longer 3 month prior Screening , baseline assessment , Has continue target knee pain despite conservative treatment ( e.g . weight reduction , physical therapy , analgesic ) , Has pain target knee demonstrate score 2 3 Western Ontario McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 ( WOMAC LK 3.1 ) A1 ( Walking Pain ) Subscale , Has mean score 1.5 3.5 Western Ontario McMaster Universities Osteoarthritis Index Likert Scale Version 3.1 ( WOMAC LK 3.1 ) A ( Pain ) Subscale . Inclusion Criteria Repeat Phase : Must major safety concern first course treatment assessed Investigator ; Must WOMAC LK 3.1 A score least 1 . Exclusion criterion : Has modify KellgrenLawrence Numerical Grading System grade IV patellofemoral compartment target knee confirm standard Xrays take longer 3 month prior Screening , baseline assessment , Has clinically apparent tense effusion target knee , Has viscosupplementation joint include target knee within 9 month prior Screening , Has concomitant inflammatory disease condition affect joint ( e.g . rheumatoid arthritis , metabolic bone disease , psoriasis , gout , symptomatic chondrocalcinosis active infection , etc. , ) Symptomatic OA contralateral knee either hip responsive paracetamol require therapy , Has relate hypersensitivity avian protein and/or component hyaluronanbased injection device ,</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Osteoarthritis knee</keyword>
	<keyword>Musculoskeletal</keyword>
</DOC>